Literature DB >> 26690867

Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Dinesh Vyas, Nicolas Lopez-Hisijos, Sulakshana Gandhi, M El-Dakdouki, Marc D Basson, Mary F Walsh, X Huang, Arpita K Vyas, Lakshmi S Chaturvedi.   

Abstract

Triple negative breast cancer exhibit increased IL-6 expression compared with matched healthy breast tissue and a strong link between inflammation and cancer progression and metastasis has been reported. We investigated whether doxorubicin-hyaluronan-super-paramagnetic iron oxide nanoparticles (DOX-HA-SPION) would show greater therapeutic efficacy in human triple negative breast cancer cells (TNBC) MDA-MB-231, as was recently shown in drug-sensitive and multi-drug-resistant ovarian cancer cells. Therefore, we measured cellular DOX uptake via confocal microscopy; observed morphologic changes: mitochondrial and nuclear changes with electron microscopy, and quantitated apoptosis using FACS analysis after Annexin V and PI staining in MDA-MB-231 cells treated with either DOX alone or DOX-HA-SPION. We also measured both proinflammatory and anti-inflammatory cytokines; IL-6, IL-10 respectively and also measured nitrate levels in the conditioned medium by ELISA. Inaddition, NF-κB activity was measured by luciferase assay. Confocal microscopy demonstrated greater cytoplasmic uptake of DOX-HA-SPION than free DOX. We also demonstrated reduction of Vimentin with DOX-HA-SPION which is significantly less than both control and DOX. DOX-HA-SPION enhanced apoptosis and significantly down regulated both pro-inflammatory mediators IL-6 and NF-κB in comparison to DOX alone. The secretion levels of anti-inflammatory mediators IL-10 and nitrate was not decreased in the DOX or DOX-HA-SPION treatment groups. Our data suggest that DOX-HA-SPION nanomedicine-based drug delivery could have promising potential in treating metastasized and chemoresistant breast cancer by enhancing the drug efficacy and minimizing off-target effects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26690867      PMCID: PMC4681409          DOI: 10.1166/jnn.2015.10834

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  95 in total

1.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

Review 2.  Understanding the dual nature of CD44 in breast cancer progression.

Authors:  Jeanne M V Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2011-10-04       Impact factor: 5.852

Review 3.  Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer.

Authors:  Bin Wang; Jenna M Rosano; Rabe'e Cheheltani; Mohan P Achary; Mohammad F Kiani
Journal:  Expert Opin Drug Deliv       Date:  2010-10       Impact factor: 6.648

Review 4.  Current and proposed biomarkers of anthracycline cardiotoxicity in cancer: emerging opportunities in oxidative damage and autophagy.

Authors:  J S Dickey; V A Rao
Journal:  Curr Mol Med       Date:  2012-07-01       Impact factor: 2.222

Review 5.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 6.  Neoadjuvant treatments for triple-negative breast cancer (TNBC).

Authors:  G von Minckwitz; M Martin
Journal:  Ann Oncol       Date:  2012-08       Impact factor: 32.976

Review 7.  Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

Authors:  Robert J Ignoffo
Journal:  Am J Health Syst Pharm       Date:  2004-11-01       Impact factor: 2.637

8.  Folic acid protected silver nanocarriers for targeted drug delivery.

Authors:  Yuling Wang; Brittany Book Newell; Joseph Irudayaraj
Journal:  J Biomed Nanotechnol       Date:  2012-10       Impact factor: 4.099

9.  Surface functionalized gold nanoparticles for drug delivery.

Authors:  Jinping Cheng; Yan-Juan Gu; Shuk Han Cheng; Wing-Tak Wong
Journal:  J Biomed Nanotechnol       Date:  2013-08       Impact factor: 4.099

Review 10.  Relapsed triple-negative breast cancer: challenges and treatment strategies.

Authors:  Valentina Guarneri; Maria Vittoria Dieci; Pierfranco Conte
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

View more
  9 in total

1.  Advanced Functional Nanomaterials for Theranostics.

Authors:  Haoyuan Huang; Jonathan F Lovell
Journal:  Adv Funct Mater       Date:  2016-11-07       Impact factor: 18.808

2.  Oocyte exposure to ZnO nanoparticles inhibits early embryonic development through the γ-H2AX and NF-κB signaling pathways.

Authors:  Jing Liu; Yong Zhao; Wei Ge; Pengfei Zhang; Xinqi Liu; Weidong Zhang; Yanan Hao; Shuai Yu; Lan Li; Meiqiang Chu; Lingjiang Min; Hongfu Zhang; Wei Shen
Journal:  Oncotarget       Date:  2017-06-27

Review 3.  Versatile Types of Polysaccharide-Based Drug Delivery Systems: From Strategic Design to Cancer Therapy.

Authors:  Yanzhen Sun; Xiaodong Jing; Xiaoli Ma; Yinglong Feng; Hao Hu
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 4.  Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence.

Authors:  Nahlah Makki Almansour
Journal:  Front Mol Biosci       Date:  2022-01-25

5.  Targeting self-assembled F127-peptide polymer with pH sensitivity for release of anticancer drugs.

Authors:  Wenzhao Han; Fanwei Meng; Hao Gan; Feng Guo; Junfeng Ke; Liping Wang
Journal:  RSC Adv       Date:  2021-01-05       Impact factor: 3.361

6.  Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?

Authors:  Dinesh Vyas; Kaivalya Deshpande; Lakshmishankar Chaturvedi; Laput Gieric; Karen Ching
Journal:  J Clin Med Res       Date:  2015-12-28

Review 7.  Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Authors:  Aikaterini Berdiaki; Monica Neagu; Eirini-Maria Giatagana; Andrey Kuskov; Aristidis M Tsatsakis; George N Tzanakakis; Dragana Nikitovic
Journal:  Biomolecules       Date:  2021-03-08

8.  Magnetosomes and Magnetosome Mimics: Preparation, Cancer Cell Uptake and Functionalization for Future Cancer Therapies.

Authors:  Zainab Taher; Christopher Legge; Natalie Winder; Pawel Lysyganicz; Andrea Rawlings; Helen Bryant; Munitta Muthana; Sarah Staniland
Journal:  Pharmaceutics       Date:  2021-03-10       Impact factor: 6.321

Review 9.  Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Hui Li Ang; Farid Hashemi; Ali Zarrabi; Amirhossein Zabolian; Kiavash Hushmandi; Masoud Delfi; Haroon Khan; Milad Ashrafizadeh; Gautam Sethi; Alan Prem Kumar
Journal:  Cells       Date:  2021-11-29       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.